“The Buzz” Show: GeoVax Labs, Inc. (NASDAQ: GOVX) Cancer Vaccine Patent | Financial Buzz

“The Buzz” Show: GeoVax Labs, Inc. (NASDAQ: GOVX) Cancer Vaccine Patent

FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “GeoVax Labs, Inc. Receives Notice of Allowance For Cancer Vaccine Patent”

GeoVax Labs, Inc. (NASDAQ: GOVX) surged 36% in premarket trading after the company received a Notice of Allowance for a cancer vaccine patent.

In general, the claims to be granted in the patent cover GeoVax’s vector platform for expressing tumor associated antigens in virus-like particles from an MVA viral vector and encompass its Mucin 1 tumor-associated antigen immunotherapy candidate.

GeoVax Labs, Inc. is a clinical-stage biotechnology company with a robust pipeline of human vaccines and immunotherapies to address unmet medical needs in cancer and infectious disease.

For more information, please visit: GeoVax Labs, Inc.

About The Buzz: A Financial Buzz Show on daily news, covering the most up to date financial information. The Buzz intends to provide factual and relevant information for its audience. The Buzz is 100% original content, created by Financial Buzz Media. Located on Wall Street in the heart of New York City’s financial district, FinancialBuzz.com is a credible source for the world’s latest trending financial and economic news. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content.

Opt-into our eNewsletter NOW! For the Latest Trending Financial News Topics in Cannabis, Tech, Biotechs, Precious Metals, Energy, Renewable Energy and much more!